Implant Sciences to Exhibit Quantum Sniffer at the ASIS International 50th Annual Seminar & Exhibits

"Quantum Sniffer" will be exhibited at the ASIS International 50th Annual Seminar & Exhibits

(PRWEB) September 27, 2004 -- Implant Sciences Corporation (AMEX: "IMX", "IMX.WS") a developer and manufacturer of products for national security, medicine and industry, today announced that its "Quantum Sniffer" will be exhibited at the ASIS International 50th Annual Seminar & Exhibits. The American Society of Industrial Security (ASIS), the world's most comprehensive educational and networking event in the security industry is meeting at the Dallas Convention Center. The Seminar is specifically designed for and by security professionals, and runs from September 27th through September 29th. Senior management and sales represenatative personnel from Implant Sciences will be located at booth 6009 on the exhibit floor.

The Quantum Sniffer is the Company's trace explosives detection device using the Company's proprietary QSTM Ion Mobility Spectrometry technology, which electronically detects minute quantities of explosive vapor molecules in the air. These units may be used to determine the presence of, or confirm the absence of, common explosives in personal equipment, packages, postal mail and cargo that may be conveyed by persons, vehicles, airplanes, and watercraft.

Dr. Anthony J. Armini, Chairman and CEO of Implant Sciences commented, “After many years of research and development, we are excited about the opportunity to unveil our production ready version of the Quantum Sniffer at this important exhibit for security professionals. The equipment to be exhibited includes devices that will soon be submitted to the US Navy and the TSA in accordance with the terms of currently existing contracts with these agencies. We look forward to a successful presentation of our new products for the security industry and look forward to the future prospects that our Quantum Sniffer holds for Implant Sciences Corporation.”

Dr. Anthony J. Armini, further stated, “I would like to thank each and every member of Implant Sciences for their hard work in every aspect of the process of bringing this product from a vision to a reality. And I would especially like to extend my gratitude to all of the shareholders, investors and business partners who have contributed their resources and money, and most importantly, their loyalty to the goal of making Implant Sciences a successful company. We hope that as a result of these many contributions, lives will be saved domestically and internationally.”

About Implant Sciences
Implant Sciences, incorporated in 1984, is using its core ion technology to develop, manufacture and market products for national security, medicine, and industry. Under development are portable and bench-top trace element detection devices to identify explosives, narcotics and other toxic materials. The Company has also received government grants from the US Army, Navy and Air Force, and the Transportation Security Administration to adapt the Company's explosive detection technology to a wide number of security requirements.

Using its proprietary ion implantation and thin film coating technologies, Implant Sciences has a sophisticated production line that modifies the surface characteristics of orthopedic joint implants to reduce polyethylene wear, thereby substantially increasing the life of the implants. The company also manufactures and markets radioactive and non-radioactive products for medical use, including radioactive seeds for treating prostate cancer that are distributed throughout the United States by its own direct sales force. In parallel with the production of these seeds, it is also developing additional brachytherapy products for the treatment of breast, eye, and other cancers.

This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe", "estimate", "project", "expect" or similar expressions. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company's products and services in the marketplace, the ability of the Company to develop effective new products and receive governmental approvals of such products, competitive factors, dependence upon third-party vendors, and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release.

# # #

Source :